← All trials
NCT03174236
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 5, 2017
- Primary completion
- Apr 30, 2020
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 2000
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- University of OxfordLead sponsor
- University of LondonCollaborator
- Coast General Hospital, Mombasa, KenyaCollaborator
- Swansea UniversityCollaborator
- University of NairobiCollaborator
- Mbale Regional Referral HospitalCollaborator
- Kenya Medical Research InstituteCollaborator
- University of OxfordOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.